Shattuck Labs Inc (STTK) News

Form 8-K - Current report

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in...

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a...

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK...

Form 8-K - Current report

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuke

– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations;...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK...

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Mye

- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN...

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the Eu

– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously...

Form 4 - Statement of changes in beneficial ownership of securities